The 15 most recent market catalysts affecting $ROIV, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Neutral
Impact 65
Stifel Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $51
Stifel analyst Alex Thompson initiated coverage on Roivant Sciences (ROIV) with a 'Buy' rating and a $51 price target. This is a positive development for Roivant as new analyst cov…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 55
TD Cowen Maintains Buy on Roivant Sciences, Raises Price Target to $55
TD Cowen analyst Yaron Werber maintained a 'Buy' rating on Roivant Sciences and raised the price target from $50 to $55. This action signals a strengthened positive outlook from a …
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $46
Guggenheim analyst Yatin Suneja maintained a 'Buy' rating on Roivant Sciences (ROIV) and raised the price target from $42 to $46. This action signals continued positive sentiment f…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $47
HC Wainwright & Co. analyst Douglas Tsao maintained a 'Buy' rating on Roivant Sciences (ROIV) and raised the price target from $41 to $47. This action indicates an analyst's increa…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 55
Jefferies Maintains Buy on Roivant Sciences, Raises Price Target to $52
Jefferies analyst Dennis Ding maintained a 'Buy' rating on Roivant Sciences (ROIV) and raised the price target from $42 to $52. This action signals increased confidence from a prom…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 75
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday
The filing details several companies that saw significant stock price increases on a day when the overall market was down. Roivant Sciences and Pharvaris NV experienced substantial…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 95
Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate
Roivant Sciences (ROIV) disclosed robust Phase 2 data for mosliciguat, a treatment for PH-ILD, a rare and serious lung condition. The drug demonstrated statistically significant re…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 95
FDA Clears First Targeted Dermatomyositis Treatment From Roivant
Roivant Sciences has secured FDA approval for LISRAYA (brepocitinib) 30 mg, a once-daily oral medication for adults with dermatomyositis. This is a significant event as LISRAYA is …
Aug 28, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $41 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating and maintained a $41 price target for Roivant Sciences (ROIV). This is a posit…
Aug 14, 2026
Market Technicals
Neutral
Impact 65
9 Health Care Stocks Whale Activity In Today’s Session
The filing highlights 'whale activity' in options for nine healthcare stocks, which is significant because large-scale options trades often precede notable stock price movements. W…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $46
Citigroup analyst Samantha Semenkow maintained a 'Buy' rating on Roivant Sciences and raised the price target from $42 to $46. This action signals a strengthened conviction in the …
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 60
Guggenheim Maintains Buy on Roivant Sciences, Raises Price Target to $42
Guggenheim analyst Yatin Suneja has maintained a 'Buy' rating on Roivant Sciences (ROIV) and raised the price target from $36 to $42. This action signals continued confidence in th…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 65
HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $41
HC Wainwright & Co. analyst Douglas Tsao has maintained a 'Buy' rating on Roivant Sciences and raised the price target from $34 to $41. This action indicates a strengthened positiv…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 65
Roivant's Priovant Announces First Patients Enrolled In Global Phase 3 BEACON+ Study Of Brepocitinib In Cutaneous Sarcoidosis; Topline Data Expected In 2028
This headline represents a moderate corporate catalyst for Roivant Sciences. The initiation of a Phase 3 trial is a significant step in drug development, indicating confidence in t…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
Roivant Sciences Q1 Adj. EPS $(0.34) Misses $(0.32) Estimate, Sales $1.442M Miss $2.057M Estimate
Roivant Sciences (ROIV) announced Q1 adjusted EPS of $(0.34), missing the $(0.32) estimate by 6.25%, and sales of $1.442 million, missing the $2.057 million estimate by a substanti…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.